The role of immune cell subpopulations in the growth and rejection of TC‑1/A9 tumors in novel mouse strains differing in the H2‑D haplotype and NKC domain

Indrová,Marie; Rossowska,Joanna; Pajtasz‑Piasecka,Elzbieta; Mikyšková,Romana; Richter,Jan; Rosina,Jozef; Sedlacek,Radislav; Fišerová,Anna

doi:10.3892/ol.2018.7763

The role of immune cell subpopulations in the growth and rejection of TC‑1/A9 tumors in novel mouse strains differing in the H2‑D haplotype and NKC domain

Authors:
- Marie Indrová
- Joanna Rossowska
- Elzbieta Pajtasz‑Piasecka
- Romana Mikyšková
- Jan Richter
- Jozef Rosina
- Radislav Sedlacek
- Anna Fišerová
View Affiliations

Affiliations: Department of Transgenic Models of Diseases, Institute of Molecular Genetics of The Czech Academy of Sciences, 252 42 Vestec, Czech Republic, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53‑114 Wroclaw, Poland, Department of Health Care Disciplines and Population Protection, Czech Technical University in Prague, Faculty of Biomedical Engineering, 27201 Kladno, Czech Republic
Published online on: January 10, 2018 https://doi.org/10.3892/ol.2018.7763
Pages: 3594-3601
Copyright: © Indrová et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to elucidate the role of cluster of differentiation (CD)8+, CD4+, natural killer (NK), and myeloid (CD11b+) cells in the course of the growth and rejection of experimental major histocompatibility complex (MHC) class I‑deficient, HPV16 E6/E7‑associated TC‑1/A9 tumors in mice. Stable mouse lines (F30) generated by inbreeding of Balb/c and C57BL/6 strains, which were characterized by H‑2Db+d‑NK1.1neg (B6‑neg) and H‑2Db‑d+NK1.1high (Balb‑high) phenotypes, were used for the present study. The novel strains spontaneously regressed tumors in 70‑90% of cases. Ex vivo histological analysis of the tumor microenvironment in cryosections showed an indirect correlation between the growth of the transplanted tumor (progressor vs. regressor mice) and the proportion of immunocompetent cell infiltration in the tumors. The regressor mice exhibited a higher infiltration of tumors with CD4+ and CD8+ cells, and in Balb‑high with NK cells as well, compared with the progressors. All tumor transplants also indicated a huge infiltration of CD11b+ cells, but this infiltration was not dependent on the stage of the TC‑1/A9 tumor development. Depletion of individual cell subpopulations in vivo exhibited different effects on the tumor development in the two strains. Elimination of CD8‑positive cells enhanced growth of TC‑1/A9 tumor transplants in both hybrid stains, whereas CD4+ cell depletion affected rejection of TC‑1/A9 tumors in the B6‑neg mice only. Depletion of NK cells with anti‑asialo GM1 antibody in the Balb‑high strain led to enhancement of tumor growth, which was more pronounced after depletion of the NK1.1+ subpopulation. On the other hand, depletion of NK cells with anti‑asialo GM1 in B6‑neg mice did not affect the regression of TC‑1/A9 tumor transplants, but increased the CD11b+ cell infiltration. In summary, these results indicate that co‑operation of particular subsets of immunocompetent cells is essential for the rejection of TC‑1/A9 tumor transplants. In B6‑neg mice, the co‑operative action of CD8+ and CD4+ cells is required, whereas in Balb‑high mice, the synergy of CD8+ and NK1.1+ cells is of major importance.

View Figures

View References

1	Swann JB and Smyth MJ: Immune surveillance of tumors. J Clin Invest. 117:1137–1146. 2007. View Article : Google Scholar : PubMed/NCBI
2	Xu D, Gu P, Pan PY, Li Q, Sato AI and Chen SH: NK and CD8⁺ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer. 109:499–506. 2004. View Article : Google Scholar : PubMed/NCBI
3	Ghiringhelli F, Apetoh L, Housseau F, Kroemer G and Zitvogel L: Links between innate and cognate tumor immunity. Curr Opin Immunol. 19:224–231. 2007. View Article : Google Scholar : PubMed/NCBI
4	Fišerová A, Richter J, Čapková K, Bieblová J, Mikyšková R, Reiniš M and Indrová M: Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors. Int J Oncol. 49:763–772. 2016. View Article : Google Scholar : PubMed/NCBI
5	Indrová M, Símová J, Bieblová J, Bubeník J and Reinis M: NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours. Oncol Rep. 25:281–288. 2011.PubMed/NCBI
6	Indrová M, Bieblová J, Rossowska J, Kuropka P, Pajtasz-Piasecka E, Bubeník J and Reinis M: HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int J Oncol. 34:173–179. 2009.PubMed/NCBI
7	Mikyšková R, Indrová M, Vlková V, Bieblová J, Šímová J, Paračková Z, Pajtasz-Piasecka E, Rossowska J and Reiniš M: DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J Leukoc Biol. 95:743–753. 2014. View Article : Google Scholar : PubMed/NCBI
8	Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA and Pilon-Thomas S: Immune checkpoint blockade to improve tumor infiltrating lymphocytes for adoptive cell therapy. PLoS One. 11:e01530532016. View Article : Google Scholar : PubMed/NCBI
9	Yu P and Fu YX: Tumor-infiltrating T lymphocytes: Friends or foes? Lab Invest. 86:231–245. 2006. View Article : Google Scholar : PubMed/NCBI
10	Smahel M, Síma P, Ludvíková V, Marinov I, Pokorná D and Vonka V: Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine. 21:1125–1136. 2003. View Article : Google Scholar : PubMed/NCBI
11	Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21–26. 1996.PubMed/NCBI
12	Mikysková R, Bubeník J, Vonka V, Smahel M, Indrova M, Bieblová J, Símová J and Jandlová T: Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy. Int J Oncol. 26:521–527. 2005.PubMed/NCBI
13	Símová J, Bubeník J, Bieblová J, Rosalia RA, Fric J and Reinis M: Depletion of T (reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours. Int J Oncol. 29:1567–1571. 2006.PubMed/NCBI
14	Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, Simova J, Jandlova T, Bubenik J and Reinis M: Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology. 123:218–227. 2008.PubMed/NCBI
15	Rossowska J, Pajtasz-Piasecka E, Szyda A, Zietara N and Duś D: Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response. Folia Histochem Cytobiol. 45:349–355. 2007.PubMed/NCBI
16	Hadrup S, Donia M and Thor Straten P: Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron. 6:123–133. 2013. View Article : Google Scholar : PubMed/NCBI
17	Luckheeram RV, Zhou R, Verma AD and Xia B: CD4⁺T cells: Differentiation and functions. Clin Dev Immunol. 2012:9251352012. View Article : Google Scholar : PubMed/NCBI
18	Koretzky GA: Multiple roles of CD4 and CD8 in T cell activation. J Immunol. 185:2643–2644. 2010. View Article : Google Scholar : PubMed/NCBI
19	Smyth MJ, Crowe NY and Godfrey DI: NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 13:459–463. 2001. View Article : Google Scholar : PubMed/NCBI
20	Bendelac A, Savage PB and Teyton L: The biology of NKT cells. Annu Rev Immunol. 25:297–336. 2007. View Article : Google Scholar : PubMed/NCBI
21	Símová J, Indrová M, Bieblová J, Mikysková R, Bubeník J and Reinis M: Therapy for minimal residual tumor disease: Beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy. Int J Cancer. 126:2997–3004. 2010.PubMed/NCBI
22	Nishikado H, Mukai K, Kawano Y, Minegishi Y and Karasuyama H: NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J Immunol. 186:5766–5771. 2011. View Article : Google Scholar : PubMed/NCBI
23	Tomar MS, Kumar S, Kumar S, Gautam PK, Singh RK, Verma PK, Singh SP and Acharya A: NK cell effector functions regulation by modulating nTreg cell population during progressive growth of Dalton's lymphoma in mice. Immunol Invest. 11:1–17. 2017.
24	da Cunha A, Antoniazi Michelin M and Cândido Murta EF: Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. Immunol Lett. 177:25–37. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zalli A, Bosch JA, Goodyear O, Riddell N, McGettrick HM, Moss P and Wallace GR: Targeting β2 adrenergic receptors regulate human T cell function directly and indirectly. Brain Behav Immun. 45:211–218. 2015. View Article : Google Scholar : PubMed/NCBI
26	Sato Y, Shimizu K, Shinga J, Hidaka M, Kawano F, Kakimi K, Yamasaki S, Asakura M and Fujii SI: Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma. Oncoimmunology. 4:e9955412015. View Article : Google Scholar : PubMed/NCBI
27	Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
28	Mikyšková R, Indrová M, Símová J, Bieblová J, Bubeník J and Reiniš M: Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine. Oncol Rep. 25:1683–1689. 2011.PubMed/NCBI
29	Gabrilovich DI, Ostrand-Rosenberg S and Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12:253–268. 2012. View Article : Google Scholar : PubMed/NCBI
30	Umansky V and Sevko A: Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron. 6:169–177. 2013. View Article : Google Scholar : PubMed/NCBI
31	Sevko A and Umansky V: Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: Thick as thieves. J Cancer. 4:3–11. 2013. View Article : Google Scholar : PubMed/NCBI